ZYNE — Zynerba Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
Brief: Zynerba Pharma Says New Data Describes Statistically Significant Results From Phase 2 Bright Trial
NASDAQ RESUMED AT 03:15 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:05 PM
Brief: Zynerba Says Meeting With FDA Planned For Q4 To Discuss Regulatory Path Forward For Zygel
Brief: Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results
U.S. STOCKS ON THE MOVE-Boeing, OptiNose, Xilinx
U.S. STOCKS ON THE MOVE-Genworth Financial, Zynerba Pharma, Bloom Energy
U.S. STOCKS ON THE MOVE-Bloom Energy, Liquidia Tech, Zynerba Pharma
Brief: Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel
Zynerba: Falls as cannabis-based drug for rare genetic disorder fails trial
U.S. STOCKS ON THE MOVE-StoneCo, Tuesday Morning, Zynerba Pharma
Brief: Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline
Zynerba: Gains on positive data from development disorder treatment study
U.S. STOCKS ON THE MOVE-Alliance Data Systems, Alibaba Group, Dexcom, Can Fite Biofarma, U.S. travel firms
Brief: Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X
Zynerba Pharma rises as gel improves condition of neurological disorder patients
Brief: Zynerba Pharmaceuticals Reports First Quarter 2020 Results
Brief: Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome
U.S. STOCKS ON THE MOVE-Mallinckrodt, Shake Shack, Tupperware, LendingTree